Mono Pharmacare share price
NSE: MONOPHARMAPharmaceuticals & Biotechnology
Mono Pharmacare Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2023 · Issue price ₹28
Last close ₹8.90up ₹0.40 (4.71%)
Share price at the NSE close on 27 Oct 2026. Previous close ₹8.50.
27 Oct: open ₹8.15, high ₹8.90, low ₹8.15
52-week range of traded prices to 27 Oct 2026
₹7.50Low, 10 Aug 2026₹22.05High, 28 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹16 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 44.40
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.50
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.79
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,000100.0% delivered
Results
Consolidated; ₹ crore.Mono Pharmacare half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −1.6%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −88.3%
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹99 Crup 49.95%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹0.33 Crup 1,417.35%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 0.3%
Revenue by half year
Peak revenue ₹99 Cr, half year to Mar 2026; lowest ₹56 Cr, half year to Mar 2024
Net profit by half year, a loss in red
| ₹ crore | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 66.5 | 55.8 | 87.2 | 81.2 | 66.3 | 99.4 |
| Net profit | 1.9 | 0.6 | 2.3 | 0.7 | 0.0 | 0.3 |
| Net margin | 2.8% | 1.0% | 2.6% | 0.9% | 0.0% | 0.3% |
Consolidated. The 6 half years from Sep 2023, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹166 Crdown 1.58%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹0.35 Crdown 88.58%
- Net margin
- 0.2%
Revenue by year
Peak revenue ₹168 Cr, year to Mar 2025; lowest ₹122 Cr, year to Mar 2024
Net profit by year, a loss in red
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 122 | 168 | 166 |
| Net profit | 2 | 3 | 0 |
| Net margin | 2.0% | 1.8% | 0.2% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Single segment, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −51.7% | −88.6% | +322.3% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mono Pharmacare competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Mono Pharmacare in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Colinz LaboratoriesCOLINZ | 17 | 6.22 | 1.73 | −8.4% | +484.3% | 28.7% | 1.7% | 0.00% |
 Star Source Multi TradeSTARSOURCE | 17 | – | 13.30 | – | – | −0.5% | −3.1% | 0.00% |
 Venmax Drugs and PharmaceuticalsVENMAX | 16 | – | – | +385.7% | – | – | – | 0.00% |
 Zenith Health CareZENITHHE | 16 | 101.10 | 2.18 | −9.3% | – | 2.2% | −1.2% | 0.00% |
 Desh Rakshak AushdhalayaDESHRAK | 15 | 27.77 | 1.15 | −24.3% | – | 4.7% | 5.8% | 0.00% |
 Beryl DrugsBERLDRG | 12 | 19.29 | 1.22 | +8.3% | +169.1% | 6.4% | 3.1% | 0.00% |
 Unjha FormulationsUNJHAFOR | 12 | 24.71 | 3.03 | +13.0% | +386.7% | 13.5% | 15.2% | 0.00% |
 Ortin GlobalORTINGLOBE | 10 | – | 8.38 | −58.3% | – | −56.2% | −52.2% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Mono Pharmacare announcements
Oct 2026
27 Oct · Results
15 Oct · Results
Sep 2026
30 Sep · Meeting
17 Sep · Corporate action
9 Sep · Updates
Mono Pharmacare share price by year
Each calendar year to 2025.Mono Pharmacare share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 15.20 | −56.1% | 34.65 | 14.95 |
| 2024 | 34.65 | −29.3% | 72.15 | 32.10 |
| 2023 | 49.00 | – | 53.85 | 29.30 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 7 Sep 2023.
Recent sessions
The 9 trading days to 23 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 2,000 | 100.0% |
| 9 Oct 2026 | 8.45 | 8.90 | 8.45 | 8.90 | 8.74 | 14,000 | 100.0% |
| 8 Oct 2026 | 8.00 | 8.75 | 8.00 | 8.50 | 8.29 | 12,000 | – |
| 7 Oct 2026 | 8.05 | 8.40 | 8.05 | 8.40 | 8.18 | 6,000 | 66.7% |
| 6 Oct 2026 | 8.30 | 8.30 | 8.30 | 8.30 | 8.30 | 2,000 | 100.0% |
| 30 Sep 2026 | 8.55 | 8.55 | 8.55 | 8.55 | 8.55 | 2,000 | 100.0% |
| 29 Sep 2026 | 8.55 | 8.55 | 8.55 | 8.55 | 8.55 | 4,000 | 100.0% |
| 28 Sep 2026 | 8.20 | 9.00 | 8.20 | 9.00 | 8.68 | 46,000 | 60.9% |
| 25 Sep 2026 | 8.60 | 8.60 | 8.60 | 8.60 | 8.60 | 10,000 | 100.0% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- MONOPHARMA
- ISIN
- INE0OIP01012
- Industry
- Pharmaceuticals & Biotechnology